On Friday, Following U.S. Stocks were among the “Top Gainers“: NeoStem Inc (NASDAQ:NBS), Trinity Industries Inc (NYSE:TRN), Dyax Corp (NASDAQ:DYAX), J C Penney Company Inc (NYSE:JCP)
NeoStem Inc (NASDAQ:NBS)’s shares picked up 3.33%, and closed at $4.03. The stock volatility for the week is 5.05%, while for the month remained 5.11%. The company holds consensus target price of $18.67.
If we consider EPS growth of the company, then we will notice the following observations:
The company showed -1.65diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 11.60% and Annual EPS growth for the past 5 years is considered as 41.40%.
The mean recommendation of analysts for this stock is 1.70 (where 1=Buy, 5=Sale).
NeoStem, Inc., a biotechnology company, develops cell based therapeutics. It is developing a Phase III targeted cancer immunotherapy product to enhance the destruction of cancer initiating cells; a Phase II ischemic repair product candidate to treat damaged heart muscle following a heart attack; a Phase II immune modulation product candidate to treat type 1 diabetes and steroid resistant asthma; and an investigational technology to repair or replace damaged or aged tissue, cells, and organs. The company, through its partner, Progenitor Cell Therapy, offers contract development and manufacturing services. It also collects, processes, and stores umbilical cord blood units and adult stem cells. NeoStem, Inc. was founded in 1980 and is headquartered in New York, New York.
Trinity Industries Inc (NYSE:TRN), raised 3.26%, and closed at $33.94. The stock has price to sale value of 0.86, however, price to book value is 1.71. With recent incline, the year-to-date (YTD) performance reflected a 21.65% gain above last year. During the past month the stocks lose -4.21%, bringing three-month performance to 22.04% and six-month performance to -28.64%. The mean recommendation of analysts for this stock is 2.10. (where 1=Buy, 5=Sale).
Trinity Industries, Inc. provides various products and services for the energy, transportation, chemical, and construction sectors in the United States and internationally. Its Rail Group segment offers railcars, counting autorack, box, covered hopper, gondola, intermodal, tank, and open hopper cars; and couplers, axles, and other equipment, in addition to railcar maintenance services. This segment serves railroads, leasing companies, and industrial shippers of various products. The company’s Railcar Leasing and Administration Services Group segment leases tank and freight railcars to industrial shippers and railroads; provides administration, maintenance, and administrative services; and manages railcar fleets on behalf of third parties.
Dyax Corp (NASDAQ:DYAX), enhanced 3.22%, and closed at $17.30, hitting new 52-week high of $17.50. The company holds the market capitalization of 2.37B. For the trailing twelve months, the stock’s return on equity value remains -11.40%, while return on assets value is - 5.60%, in response to its return on investment value of -0.70%. Its 20-day moving average gained 10.38%, above 50-day moving average of 14.28%, above 200-day moving average of - 46.89% from the latest market price of $17.30. The mean recommendation of analysts for this stock is 1.60.(where 1=Buy, 5=Sale).
Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and plasma kallikrein-mediated (PKM) angioedemas. The company offers KALBITOR for the treatment of acute attacks of HAE. It is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein, which would be a candidate to prophylactically treat HAE and other PKM disorders. The company distributes KALBITOR through a network of wholesale and specialty pharmacy arrangements. It has agreements with CVie Therapeutics for the development and commercialization of KALBITOR in the treatment of HAE and other angioedema indications in China; and Novellus Biopharma AG for the development and commercialization of KALBITOR for the treatment of HAE and other angioedema indications in Latin America, counting Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela.
J C Penney Company Inc (NYSE:JCP), rose 3.20%, and closed at $7.73. The stock has the beta value of 1.92, and its volatility for the week is 4.00%, while for the month it is 4.23%. The company has the market capitalization of $ 2.36B. The company holds the book value per share of 7.96, whereas cash per share is 2.24. Price to book value is estimated to be 0.97, while price to sale value is 0.19. Analysts mean recommendation for the stock is said to be 3.30 (where 1=Buy, 5=sale).
J C. Penney Company, Inc., through its partner, J. C. Penney Corporation, Inc., sells merchandise through department stores in the United States. The company sells family apparel and footwear, accessories, fine and fashion jewelry, beauty products, and home furnishings, in addition to provides various services, counting styling salon, optical, portrait photography, and custom decorating. As of February 26, 2015, it operated about 1,060 stores. The company also sells its products through its Website, jcp.com. J. C. Penney Company, Inc. was founded in 1902 and is based in Plano, Texas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
